Quick Answer
Seres Therapeutics, Inc. reported Cash and Equivalents of $45.77 million for fiscal year 2025.
Seres Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $45.77M | +48.6% |
| 2024 | $30.79M | -75.9% |
| 2023 | $127.97M | -21.5% |
| 2022 | $163.03M | -9.4% |
| 2021 | $180.00M | +55.1% |
| 2020 | $116.05M | +78.2% |
| 2019 | $65.13M | -24.1% |
| 2018 | $85.82M | +137.8% |
| 2017 | $36.09M | -33.8% |
| 2016 | $54.54M | -26.2% |
| 2015 | $73.93M | -35.3% |
| 2014 | $114.19M | +6803.6% |
| 2013 | $1.65M | -73.4% |
| 2012 | $6.21M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $47.64M | -28.7% | +5.0% |
| June 30, 2025 | $45.38M | -36.3% | -22.9% |
| March 31, 2025 | $58.85M | -47.1% | +91.1% |
| December 31, 2024 | $30.79M | -75.9% | -53.9% |
| September 30, 2024 | $66.82M | -60.7% | -6.2% |
| June 30, 2024 | $71.23M | -69.0% | -35.9% |
| March 31, 2024 | $111.18M | +17.2% | -13.1% |
| December 31, 2023 | $127.97M | -21.5% | -24.7% |
- Seres Therapeutics, Inc. showed an increase of +48.6% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2012–2025 period, Seres Therapeutics, Inc.’s cash and equivalents has grown by 636.4% (from $6.21 million to $45.77 million).
- The most recent figure is from Seres Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: